Celgene Corp. | Ownership
Companies that own Celgene Corp.
The Vanguard Group, Inc.
50,937,201
7.24%
-1,739,935
0.16%
06/30/2018
BlackRock Fund Advisors
39,336,027
5.59%
-2,231,355
0.19%
06/30/2018
SSgA Funds Management, Inc.
28,588,600
4.07%
-1,615,681
0.2%
06/30/2018
Edgewood Management LLC
13,924,544
1.98%
1,943,607
4.44%
06/30/2018
Orbis Investment Management Ltd.
10,255,794
1.46%
3,855,062
3.56%
06/30/2018
Northern Trust Investments, Inc.
9,198,192
1.31%
-428,507
0.2%
06/30/2018
Geode Capital Management LLC
9,189,754
1.31%
491,953
0.22%
06/30/2018
Henderson Global Investors Ltd.
9,070,041
1.29%
-369,022
0.37%
06/30/2018
Fidelity Management & Research Co.
7,973,653
1.12%
1,114,338
0.08%
06/30/2018
Norges Bank Investment Management
6,904,337
0.98%
937,908
0.09%
12/31/2017
| Address |
86 Morris Avenue
Summit New Jersey 07901
United States
|
|
Employees
|
- |
| Website |
http://www.celgene.com |
| Updated |
07/08/2019 |
| Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its targeting areas include intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The company's products include Revlimid, Vidaza, Thalomid, Pomalyst/Imnovid, Abraxane, and Istodax. |
